A multilayered approach to the analysis of genetic data from individuals with suspected albinism.


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
27 Nov 2023
Historique:
received: 01 12 2022
accepted: 12 05 2023
medline: 29 11 2023
pubmed: 18 7 2023
entrez: 17 7 2023
Statut: epublish

Résumé

Albinism is a clinically and genetically heterogeneous group of conditions characterised by visual abnormalities and variable degrees of hypopigmentation. Multiple studies have demonstrated the clinical utility of genetic investigations in individuals with suspected albinism. Despite this, the variation in the provision of genetic testing for albinism remains significant. One key issue is the lack of a standardised approach to the analysis of genomic data from affected individuals. For example, there is variation in how different clinical genetic laboratories approach genotypes that involve incompletely penetrant alleles, including the common, 'hypomorphic'

Identifiants

pubmed: 37460203
pii: jmg-2022-109088
doi: 10.1136/jmg-2022-109088
pmc: PMC10715518
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1245-1249

Subventions

Organisme : Wellcome Trust
Pays : United Kingdom

Informations de copyright

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: EB is a paid consultant and equity holder of Oxford Nanopore, a paid consultant to Dovetail, and a non-executive director of Genomics England, a limited company wholly owned by the UK Department of Health and Social Care. All other authors declare no competing interests. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care.

Références

Eur J Hum Genet. 2022 Feb;30(2):150-159
pubmed: 33981013
Nature. 2018 Oct;562(7726):268-271
pubmed: 30258228
Genet Med. 2020 Oct;22(10):1613-1622
pubmed: 32565547
NPJ Genom Med. 2022 Jan 13;7(1):2
pubmed: 35027574
Nat Commun. 2022 Jul 8;13(1):3939
pubmed: 35803923
Gene Expr. 1991 May;1(2):103-10
pubmed: 1820207
Prog Retin Eye Res. 2022 Nov;91:101091
pubmed: 35729001
Pigment Cell Melanoma Res. 2014 Jul;27(4):552-64
pubmed: 24739399
Pigment Cell Melanoma Res. 2018 Jul;31(4):466-474
pubmed: 29345414
Front Genet. 2019 May 07;10:426
pubmed: 31134132
FASEB J. 2001 Oct;15(12):2149-61
pubmed: 11641241
Nat Genet. 2022 Nov;54(11):1587-1588
pubmed: 36303073
Genet Med. 2021 Mar;23(3):479-487
pubmed: 33100333
Ophthalmology. 2018 Dec;125(12):1953-1960
pubmed: 30098354
Commun Biol. 2019 May 20;2:186
pubmed: 31123710
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Genet Med. 2020 Apr;22(4):745-751
pubmed: 31848469
J Clin Invest. 1991 Mar;87(3):1046-53
pubmed: 1900307
Mol Vis. 2012;18:38-54
pubmed: 22259223
Br J Ophthalmol. 2019 Sep;103(9):1239-1247
pubmed: 30472657

Auteurs

Panagiotis I Sergouniotis (PI)

Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.
European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL- EBI), Wellcome Genome Campus, Cambridge, UK.
Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.
Manchester Royal Eye Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Vincent Michaud (V)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.
INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

Eulalie Lasseaux (E)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.

Christopher Campbell (C)

Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Claudio Plaisant (C)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France.

Sophie Javerzat (S)

INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

Ewan Birney (E)

European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL- EBI), Wellcome Genome Campus, Cambridge, UK.

Simon C Ramsden (SC)

Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Graeme C Black (GC)

Division of Evolution, Infection and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.
Manchester Centre for Genomic Medicine, Saint Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK.

Benoit Arveiler (B)

Department of Medical Genetics, University Hospital of Bordeaux, Bordeaux, France panagiotis.sergouniotis@manchester.ac.uk benoit.arveiler@chu-bordeaux.fr graeme.black@manchester.ac.uk.
INSERM U1211, Rare Diseases, Genetics and Metabolism, University of Bordeaux, Bordeaux, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH